Sunlight addiction and hope for hair loss

Here are this week's most popular tweets on the @F1000 feed, as well as some other interesting picks from the rest of Twitter...

Continue reading

Posted in Tweet stuff | Leave a comment

Patient advocacy: access to scientific information and expert advice

Our latest #F1000talks live chat discussed how patient advocates find scientific information and expert advice. We had a great turnout of patients, patient advocates, research scientists and clinicians, and we were delighted to hear their ideas and questions.

We have summed up the discussion with a Storify. We hope you enjoy our monthly tweet chats, and if you would like to suggest a topic for one of our upcoming chats, please tweet us using #F1000talks. Hope to “see” you at the next live chat!
Continue reading

Posted in #F1000talks, Communication, Community, tweet chat, Tweet stuff | Tagged , | Leave a comment

Mark Millan wins Ariens Prize

Mark MillanPharmacology Faculty Member Mark Millan has won the 2014 Ariens Prize. The award is an annual prize organized by the Dutch Pharmacological Society in memory of the Dutch pharmacologist, Everhardus Jacobus Ariens, who made important contributions to understanding of the function of receptors in the field of pharmacology. Prize-winners are invited to present the Ariens Lecture.

Previous winners include Nobel prize winners and F1000 Faculty: Geoffrey Burnstock, Marc Caron, Urs A Meyer, Peter Barnes, Graeme Milligan , Brian Kobilka and Terry Kenakin.

Many congratulations from F1000, Mark!

Posted in Awards/honors, Pharmacology & Drug Discovery | Tagged , , | Leave a comment

Hotspots, halites and maturing memories

Here are the week's most popular tweets from @F1000, as well as other interesting gems from the rest of Twitter...

Continue reading

Posted in Tweet stuff | Leave a comment

Reverse brain gain in India – steering a course back home

Guest post by F1000 Specialist Sowmini Kumaran from Rutgers, USA who recently moved to India seeking industrial job opportunities in India.

By Adrien Facélina (eriollsdesigns – Lanthys Icon Set (for KDE)) [LGPL (http://www.gnu.org/licenses/lgpl.html)] via Wikimedia Commons

In recent years, there’s been an increasing trend of overseas Indians moving back home. The decision to move back might be due to a desire to return to one’s roots or determined by career opportunities. Whatever the reason for migration, India needs scientists who have acquired international experience and knowledge to help boost the country’s scientific innovations. There are various aspects which impact the reverse migration of Indians from across the globe. For example, job opportunities, working conditions, financial issues and prevailing cultural norms.

The Indian government, together with local scientific authorities, is currently trying a number of approaches to increase the influx of overseas scientists. There are several schemes including the DBT-Wellcome Trust, the Ramanujan Fellowship and Ramalingaswami Re-entry Fellowships offering young achievers an opportunity to take up independent research within the country. India also offers contractual and short-term research positions through various programs such as the Innovation in Science Pursuit for Inspired Research (INSPIRE) Faculty Scheme, the Assured Opportunity for Research Career (AORC) and the Jawaharlal Nehru Science Fellowship (JNSF) for taking up teaching and research assignments. A small number of my colleagues have received these fellowships. India bioscience, a not-for-profit outreach initiative organizes an annual Young Investigator Meeting every year to create awareness about job opportunities in India. More than 50 young investigators have found a career in India through attending this annual meeting.

However, a concerted approach is required to attract and retain the best talent from abroad and India. Although many of India’s prestigious rese­arch institutes have world-class facilities, their visibility outside of the country is rather poor. Thus, a sustainable infrastructure for growth and investment is required to generate a more global presence. Along with established research institutions including the Indian Institutes of Technology (IIT) and the Indian Institutes of Science Education and Research (IISER), independent research at universities and colleges should be promoted by providing more funding for state-of-the-art research facilities, and by the hiring of world-leading scientists to drive these facilities forward. In my opinion, this will not only motivate young students to consider scientific research as a worthwhile and rewarding career path, but also encourage overseas scientists to call India home once again.

For those seeking to embark on an industrial research position, recruitment is steadily rising. Several multinational companies invest in carrying out research in India because of access to raw materials and skilled labor, as well as the prospect of market growth and the need to be close to potential customers. A number of major pharmaceutical and biotechnology companies – Abott, Astra Zeneca, Aventis Pharma, Burrough-Wellcome, GlaxoSmithKline, Merck India, Novartis, and Pfizer – are basing their primary research facilities in India, creating a variety of opportunities in research and development, as well as technology transfer. The growth of the Indian pharmaceutical industry has been remarkable.

Over the past few months, I have been looking for industrial job opportunities in India. Looking for a new job is never easy, but with the growth of biomedical research in India, I look forward to finding a new role that complements my skills very soon!

Posted in Careers, Guest post | Tagged | Leave a comment

‘Root’ planning and an ‘ear-y’ correlation

Here are this week's most popular tweets on the @F1000 feed, as well as some other interesting picks from the rest of Twitter...

Continue reading

Posted in Tweet stuff | Leave a comment

Joep Lange

Joep Lange

It is with great sadness that we note the tragic death of Professor Joep Lange, F1000Prime Section Head for HIV Infection & AIDS: Clinical, in the Malaysian Airline flight MH17 disaster yesterday.

Professor Lange was Professor of Internal Medicine at the Academic Medical Centre, University of Amsterdam, and held a number of prestigious positions, including Senior Scientific Advisor to the International Antiviral Therapy Evaluation Centre, co-director of the HIV Netherlands Australia Research Collaboration (HIV-NAT) and former president of the International AIDS Society (IAS), 2002-2004.

Professor Lange and his partner, Jacqueline van Tongeren, were en route from Amsterdam to the 20th International Aids Conference in Melbourne, Australia, when their flight went down over Eastern Ukraine. Whilst the passenger manifest has not yet been released at the time of writing, if the reports that as many as a hundred researchers and activists in the HIV and AIDS fields were on board are confirmed, it would represent a terrible loss in the fight against HIV/AIDS. At the IAS’ press conference on the MH17 crash, spokesman Michael Kessler spoke of how the community had “truly lost a giant”.

A statement from Professor Marcel Levi of the Academic Medical Centre, Amsterdam, can be read here (in Dutch).

At this time, our thoughts are with Professor Lange’s colleagues, friends and family, and those of the other passengers on board flight MH17. Our deepest condolences and sympathy to all those affected by this terrible tragedy.

Posted in Faculty Members, Infectious diseases, Obituary | Tagged , , | 2 Comments

#F1000Talks: patient advocacy & accurate scientific information

Patient advocate tweet chat adOur next #F1000Talks tweet chat will discuss how patient advocates gather scientific information and expert advice, and will take place on July 24th at 1 PM EST/6 PM GMT. Our guests will be AnneMarie Ciccarella (@chemobrainfog), Lori Marx-Rubiner (@regrounding), Amy Price (@AmyPricePhD) and David Gilbert (@DavidGilbert43).

Most patients need help to understand information about their disease. Advocates can assist patients to better understand their condition in order to help them make an informed decision in getting the care that meets their requirements and goals.

Patient advocacy is a calling. Patient advocates, in addition to providing medical literature and research services to patients and their families, also liaise between patients and health care providers, educate about the best use of health plans, and provide information on how and where to obtain needed care.

Patient advocates may be individuals who work independently or are affiliated with the institution that is responsible for the patient’s care. There are also many patient advocate organizations, such as government consumer advocacy agencies, that provide services to the public. Individual patient advocates often have a professional background in social work or healthcare law, or might be health care professionals, or former patients who have made a vocation in helping patients in their decision-making.

With so many web-based resources, patients today can find health information from credible scientific sources, such as MedlinePlus and Healthfinder.gov, as well as from non-peer reviewed sources like online patient forums. While it is important that research findings make their way to the general public to better equip patients with information about their treatment options, public health officials recognize that ‘the potential for harm from inaccurate information…is significant‘. As such, patient advocates have a crucial job in helping patients evaluate the quality and appropriateness of scientific information.

Join us on July 24 to hear how our guests tackle the task of gathering scientific information, and share your ideas and concerns on the topic. As usual, our tweet chat will start with a 15 minute Q&A session, after which our guests will answer questions from the audience. For some general information about tweet chats and how to participate, see our previous blog post on the topic.

Posted in Education, Literature, Medicine, Social Media, Tweet stuff | Tagged , | Leave a comment

Carlos F. Barbas III

Carlos BarbasWe regretfully note the death of Carlos F. Barbas III, who passed away at the age of 49 last month after suffering from a rare form of medullary thyroid cancer.

An award-winning and renowned organic chemist, Carlos worked towards developing novel drugs to treat human disease; among his accomplishments are the development of new classes of drugs, either approved for clinical use already or under current trial, and the foundation of three new pharmaceutical companies. He joined the Chemical Biology Faculty in 2004 and authored over 40 recommendations on F1000Prime.

We offer our deepest sympathy to his family, friends and colleagues.

For more information on Carlos and his work, please see The Scientist‘s article and The Scripps Research Institute’s announcement.

Posted in Chemical Biology, Faculty, Faculty Members, Obituary | Leave a comment

Academy of Medical Sciences’ New Fellows 2014

Academy of Medical Sciences' New Fellows 2014The Academy of Medical Sciences recently elected 44 new Fellows to its academy, and we are delighted that a good handful of F1000Prime Section Heads and Faculty Members were on this list. Many congratulations to the following F1000Prime Faculty!

Section Heads
Janet Thornton, Bioinformatics (Genomics & Genetics)
Sebastian Johnston, Respiratory Infections, (Respiratory Disorders)
Angus Lamond, Nuclear Structure & Function (Cell Biology)

Faculty Members
Antony Carr, Nuclear Structure & Function (Cell Biology)
Tim Elliott, Immunity to Infections (Immunology)
Paul Matthews, Neuroimaging (Neurological Disorders)
Cathy Price, Cognitive Neuroscience (Neuroscience)
Paul Riley, Medical Genetics (Genomics & Genetics)
Nadia Rosenthal, Morphogenesis & Cell Biology (Developmental Biology)
Hywel Williams, Atopic Dermatitis & Other Forms of Eczema, (Dermatology)

Posted in Awards/honors, Faculty Members | Leave a comment